174 related articles for article (PubMed ID: 37286927)
1. Meaningful Within-Patient Change on the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ): Analysis of Phase III Clinical Trial Data of Daridorexant.
Phillips-Beyer A; Kawata AK; Kleinman L; Kinter DS
Pharmaceut Med; 2023 Jul; 37(4):291-303. PubMed ID: 37286927
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.
Fietze I; Bassetti CLA; Mayleben DW; Pain S; Seboek Kinter D; McCall WV
Drugs Aging; 2022 Oct; 39(10):795-810. PubMed ID: 36098936
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ).
Hudgens S; Phillips-Beyer A; Newton L; Seboek Kinter D; Benes H
Patient; 2021 Mar; 14(2):249-268. PubMed ID: 33131027
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.
Mignot E; Mayleben D; Fietze I; Leger D; Zammit G; Bassetti CLA; Pain S; Kinter DS; Roth T;
Lancet Neurol; 2022 Feb; 21(2):125-139. PubMed ID: 35065036
[TBL] [Abstract][Full Text] [Related]
5. Meaningful Within-Patient Change in Subjective Total Sleep Time in Patients with Insomnia Disorder: An Analysis of the Sleep Diary Questionnaire Using Data from Open-Label and Phase III Clinical Trials.
Phillips-Beyer A; Kawata AK; Kleinman L; Seboek Kinter D; Flamion B
Pharmaceut Med; 2024 Mar; 38(2):133-144. PubMed ID: 38302765
[TBL] [Abstract][Full Text] [Related]
6. Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Chalet FX; Luyet PP; Rabasa C; Vaillant C; Saskin P; Ahuja A; Citrome L
Postgrad Med; 2024 May; 136(4):396-405. PubMed ID: 38814132
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.
Kunz D; Dauvilliers Y; Benes H; García-Borreguero D; Plazzi G; Seboek Kinter D; Coloma P; Rausch M; Sassi-Sayadi M; Thein S
CNS Drugs; 2023 Jan; 37(1):93-106. PubMed ID: 36484969
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Summary of Research: Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ).
Hudgens S; Phillips-Beyer A; Newton L; Kinter DS; Benes H
Adv Ther; 2023 Jun; 40(6):2573-2576. PubMed ID: 37099213
[TBL] [Abstract][Full Text] [Related]
10. The burden of untreated insomnia disorder in a sample of 1 million adults: a cohort study.
Grandner M; Olivieri A; Ahuja A; Büsser A; Freidank M; McCall WV
BMC Public Health; 2023 Aug; 23(1):1481. PubMed ID: 37537544
[TBL] [Abstract][Full Text] [Related]
11. Use of the single-item Patient Global Impression-Severity scale as a self-reported assessment of insomnia severity.
Snyder ES; Tao P; Svetnik V; Lines C; Herring WJ
J Sleep Res; 2021 Feb; 30(1):e13141. PubMed ID: 33210445
[TBL] [Abstract][Full Text] [Related]
12. Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem.
Di Marco T; Scammell TE; Meinel M; Seboek Kinter D; Datta AN; Zammit G; Dauvilliers Y
CNS Drugs; 2023 Jul; 37(7):639-653. PubMed ID: 37477771
[TBL] [Abstract][Full Text] [Related]
13. Impact of group treatment for insomnia on daytime symptomatology: Analyses from a randomized controlled trial in primary care.
Sandlund C; Hetta J; Nilsson GH; Ekstedt M; Westman J
Int J Nurs Stud; 2018 Sep; 85():126-135. PubMed ID: 29886347
[TBL] [Abstract][Full Text] [Related]
14. Daridorexant in Insomnia Disorder: A Profile of Its Use.
Nie T; Blair HA
CNS Drugs; 2023 Mar; 37(3):267-274. PubMed ID: 36754930
[TBL] [Abstract][Full Text] [Related]
15. The effect of cognitive and behavioral therapy for insomnia on week-to-week changes in sleepiness and sleep parameters in patients with comorbid insomnia and sleep apnea: a randomized controlled trial.
Sweetman A; McEvoy RD; Smith S; Catcheside PG; Antic NA; Chai-Coetzer CL; Douglas J; O'Grady A; Dunn N; Robinson J; Paul D; Williamson P; Lack L
Sleep; 2020 Jul; 43(7):. PubMed ID: 31927569
[TBL] [Abstract][Full Text] [Related]
16. Quantitative measurement properties and score interpretation of the Cough Severity Diary in patients with chronic cough.
Martin Nguyen A; Bacci E; Dicpinigaitis P; Vernon M
Ther Adv Respir Dis; 2020; 14():1753466620915155. PubMed ID: 32345170
[TBL] [Abstract][Full Text] [Related]
17. Daridorexant for the treatment of insomnia disorder: findings and implications.
Dos Santos JBR; da Silva MRR
Eur J Clin Pharmacol; 2022 Nov; 78(11):1749-1761. PubMed ID: 36098753
[TBL] [Abstract][Full Text] [Related]
18. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.
Herring WJ; Connor KM; Snyder E; Snavely DB; Morin CM; Lines C; Michelson D
Sleep Med; 2019 Apr; 56():219-223. PubMed ID: 30522875
[TBL] [Abstract][Full Text] [Related]
19. Validation of the PRUCISION Instruments in Pediatric Patients with Progressive Familial Intrahepatic Cholestasis.
Gwaltney C; Ivanescu C; Karlsson L; Warholic N; Kjems L; Horn P
Adv Ther; 2022 Nov; 39(11):5105-5125. PubMed ID: 36066745
[TBL] [Abstract][Full Text] [Related]
20. Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine.
Speck RM; Yu R; Ford JH; Ayer DW; Bhandari R; Wyrwich KW
Headache; 2021 Mar; 61(3):511-526. PubMed ID: 33481276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
